Last updated: 11/03/2018 20:35:51
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination with Trametinib in Subjects with BRAF V600 Mutation-Positive Melanoma
GSK study ID
200104
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination with Trametinib in Subjects with BRAF V600 Mutation-Positive Melanoma
Trial description: This is a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and trametinib combination therapy in subjects with BRAF V600 mutation-positive, unresectable or metastatic Acral lentiginous or cutaneous melanoma. This study will evaluate the objective response rate (ORR), progression free survival (PFS), duration of response, overall survival (OS), safety and efficacy, to assess steady state (all subjects) exposure to dabrafenib, dabrafenib metabolites, and trametinib and characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of dabrafenib and trametinib. Subjects will be enrolled and will receive dabrafenib 150 milligram (mg) orally twice daily and trametinib 2 mg orally once daily. Treatment will continue until disease progression, death, unacceptable toxicity, or withdrawal of consent, or study closure. After treatment discontinuation, subjects will be followed for survival and disease progression as applicable.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
N\A
Primary outcomes:
Objective Response Rate (ORR)
Timeframe: Up to 36 months
Secondary outcomes:
To evaluate the antitumor activity by assessing the progression-free survival (PFS)
Timeframe: Up to 36 months
To evaluate the antitumor activity by assessing the duration of response
Timeframe: Up to 36 months
To evaluate the antitumor activity by assessing the overall survival (OS)
Timeframe: Approximately 5 years
To assess exposures to dabrafenib, dabrafenib metabolites, and trametinib, and characterize the population pharmacokinetics of dabrafenib and trametinib
Timeframe: Pre-dose (within 30 minutes prior to dosing) and 1, 2, 4, 6, and 8 hours after dosing on Day 15. For subjects in China: Pre-dose (within 30 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours after dosing on Day 1 and Day 15
Safety and Tolerability of dabrafenib and trametinib as assessed by Physical examinations
Timeframe: Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)
Safety and Tolerability of dabrafenib and trametinib as assessed by vital signs
Timeframe: Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)
Safety and Tolerability of dabrafenib and trametinib as assessed by 12-lead electrocardiograms (ECG), echocardiogram (ECHO)
Timeframe: ECG Screening, Day 15, Week 4, 8 and 12, every 12 weeks after Week 12 and treatment Discontinuation(approximately 1 year but can be up to 5 years). ECHO Screening, Week 4 and every 12 weeks
Safety and Tolerability of dabrafenib and trametinib as assessed by eye examinations
Timeframe: Screening and Week 4 and as clinically warranted
Safety and Tolerability of dabrafenib and trametinib by laboratory assessments
Timeframe: Screening, every 4 weeks and at treatment Discontinuation (approximately 1 year but can be up to 5 years)
Safety and Tolerability of dabrafenib and trametinib as assessed adverse events (AEs)
Timeframe: From the first dose of study treatment until 30 days after discontinuation of study treatment (approximately 1 year but can be up to 5 years)
Interventions:
Enrollment:
65
Primary completion date:
2018-18-04
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Cancer
Product
dabrafenib
Collaborators
None
Study date(s)
N/A to December 2018
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
none
- Signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- >=18 years of age.
- Primary mucosal or ocular melanoma.
- Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib, vemurafenib, LGX818, and XL281/BMS-908662) or a MEK inhibitor (including but not limited to trametinib, AZD6244, and RDEA119).
Inclusion and exclusion criteria
Inclusion criteria:
- Signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- >=18 years of age.
- Histologically confirmed acral lentiginous or cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and BRAF V600 mutation-positive. The test will be conducted at a designated central laboratory.
- Measurable disease (i.e., present with at least one measurable lesion) by RECIST version1.1.
- Performance status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
- All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values) must be <=Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0) at the time of enrolment.
- Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- Women of child-bearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception, from 14 days prior to enrolment, throughout the treatment period and for 4 months after the last dose of study treatment.
- Adequate baseline organ function as defined below: Absolute Neutrophil Count:>= 1.2 × 10^9/liter (L); Hemoglobin: >=9 grams (g)/deciliter (dL); Platelet count: >=100 x 10^9/L; Prothrombin Time/International Normalized Ratio (INR) (Subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to enrolment) and Partial Thromboplastin Time: <=1.5 x Upper Limit of Normal (ULN); Albumin: >=2.5 g/dL; Total bilirubin: <=1.5 x ULN; Aspartate aminotransferase and Alanine aminotransferase: <=2.5 x ULN; Calculated creatinine clearance (Calculate creatinine clearance using standard Cockcroft-Gault formula): >=50 milliliter (mL)/ minute (min); Left Ventricular Ejection Fraction (LVEF) (ECHO scans must be used throughout the study) : >= Lower limit of normal (LLN) by ECHO.
- Subjects with East Asian origin.
Exclusion criteria:
- Primary mucosal or ocular melanoma.
- Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib, vemurafenib, LGX818, and XL281/BMS-908662) or a MEK inhibitor (including but not limited to trametinib, AZD6244, and RDEA119).
- Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic anti-cancer therapy, or immuno anti-cancer therapy within 21 days prior to enrolment /or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrolment. (Note: Ipilimumab, pembrolizumab and nivolumab treatment must ended at least 8 weeks prior to enrollment).
- Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days), whichever is shorter, prior to enrolment. (Note: in case ipilimuamb, pembrolizmab and nivolumab are investigational drug in the regions and countries, and in case of PD-L1 antibody, these investigational treatment must have ended at least 8 weeks prior to enrollment ).
- Current use of a prohibited medication.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).
- A history of Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and/or HCV will be permitted).
- Leptomeningeal or brain metastases or metastases causing spinal cord compression that are: symptomatic or untreated or not stable for 3 months (must be documented by imaging) or requiring corticosteroids. Subjects on a stable dose of corticosteroids >1 month or on replacement dose only, or have been off of corticosteroids for at least 2 weeks can be enrolled with approval of the medical monitor. Subjects must also be off of enzyme-inducing anticonvulsants for >4 weeks.
- History of another malignancy. Exception: Subjects who have been disease-free for 3 years, of study enrolment with exceptions below. Exception: Subjects with a history of completely resected non-melanoma skin cancer, or subjects with indolent second malignancies are eligible only after the approval of the sponsor’s medical monitor.
- History of malignancy with confirmed activating RAS mutation at any time. Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility
- Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject’s safety, obtaining informed consent, or compliance with study procedures.
- A history or evidence of cardiovascular risk including any of the following: Current LVEF < Institutional LLN; A QTc interval corrected for heart rate >=480 millisecond (msec) (using Bazett’s formula); A history or evidence of current clinically significant uncontrolled arrhythmias. Clarification: Subjects with atrial fibrillation controlled for >30 days prior to dosing are eligible; A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; A history or evidence of current >=Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines; Patients with intra-cardiac defibrillators; Treatment refractory hypertension defined as a blood pressure of systolic >140 millimeters of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled by anti-hypertensive therapy; Known cardiac metastases; Abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
- Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia, hypocalcaemia determined by blood chemistry), long QT syndrome or taking medicinal products known to prolong the QT interval.
- A history or current evidence of retinal vein occlusion (RVO) .
- Pregnant or nursing females.
- History of or current diagnosis of interstitial lung disease or pneumonitis.
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
No longer a GSK study
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website